A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity scoreanalysis.

Antonio Carroccio, Mario Cottone, Sebastiano Siringo, Filippo Mocciaro, Sara Renna, Rosalba Orlando, Antonio Carroccio, Fabio Salvatore Macaluso, Antonio Carroccio, Marco Mendolaro, Dario Pluchino, Marco Ventimiglia, Serena Garufi, Concetta Ferracane, Valentina Pisana, Antonio Carroccio, Sebastiano Siringo, Antonio Magnano, Gaetano Inserra, Roberto Di MitriAntonino Carlo Privitera, Antonio Magnano, Ambrogio Orlando, Walter Fries, Maria Cappello, Giuseppe Scarpulla

Risultato della ricerca: Articlepeer review

6 Citazioni (Scopus)

Abstract

BACKGROUND:Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis.AIMS:We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis.METHODS:118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up.RESULTS:Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant.CONCLUSION:Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.
Lingua originaleEnglish
pagine (da-a)1292-1298
Numero di pagine7
RivistaDigestive and Liver Disease
Volume50
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Entra nei temi di ricerca di 'A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity scoreanalysis.'. Insieme formano una fingerprint unica.

Cita questo